Trial Profile

A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed With Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in The MA.17 Study).

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Feb 2022 Results (n=1735) devloping a tool for identification of women with limited treatment benefit published in the Breast Cancer Research and Treatment
11 Apr 2021 Results of a secondary analysis of large adjuvant endocrine therapy trials (MA.17, MA.17R and MA.27) quantify the impact of competing risks on estimates of disease recurrence and benefit from therapypublished in the European Journal of Cancer
10 Jan 2017 Planned End Date changed from 1 Nov 2016 to 1 Feb 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com